Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading SRPT stock to Hold from Buy.

Notably, ELEVIDYS had been a big piece of Sarepta's growth story as it contributed more than 50% of sales in the Q4'2024 quarter. The shares closed the day at $63.77, down 9.4% from previous close.

Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was and whether it warranted making the drug available for patients facing a ...

Shares of Sarepta Therapeutics (SRPT) are under pressure on Tuesday after the company shared a safety update related to its Elevidys, the only ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

Elevidys, Sarepta’s gene therapy for DMD, has demonstrated significant commercial success since receiving expanded label approval for patients aged 6 and older. The therapy has exceeded revenue ...

After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.

A patient died from liver injury while taking the gene therapy Elevidys Sarepta says more than 800 patients have received the ...

Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...